Macrophages and Urokinase Plasminogen Activator Receptor System in Multiple Myeloma: Case Series and Literature Review.
macrophages
multiple myeloma
urokinase plasminogen activator receptor
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Jun 2023
23 Jun 2023
Historique:
received:
05
05
2023
revised:
10
06
2023
accepted:
20
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
The microenvironment plays an essential role in multiple myeloma (MM) development, progression, cell proliferation, survival, immunological escape, and drug resistance. Mesenchymal stromal cells and macrophages release tolerogenic cytokines and favor anti-apoptotic signaling pathway activation, while the urokinase plasminogen activator receptor (uPAR) system contributes to migration through an extracellular matrix. Here, we first summarized the role of macrophages and the uPAR system in MM pathogenesis, and then we reported the potential therapeutic effects of uPAR inhibitors in a case series of primary MM-derived adherent cells. Our preliminary results showed that after uPAR inhibitor treatments, interleukein-6 (mean ± SD, 8734.95 ± 4169.2 pg/mL vs. 359.26 ± 393.8 pg/mL, pre- vs. post-treatment;
Identifiants
pubmed: 37445697
pii: ijms241310519
doi: 10.3390/ijms241310519
pmc: PMC10341390
pii:
doi:
Substances chimiques
Receptors, Urokinase Plasminogen Activator
0
Urokinase-Type Plasminogen Activator
EC 3.4.21.73
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43
pubmed: 12461559
Eur J Cancer. 2006 Apr;42(6):717-27
pubmed: 16520032
J Cell Physiol. 1994 Mar;158(3):398-407
pubmed: 8126064
Am J Hematol. 2022 Aug;97(8):1086-1107
pubmed: 35560063
Sci Rep. 2017 Aug 24;7(1):9388
pubmed: 28839232
Leuk Lymphoma. 2013 Oct;54(10):2112-21
pubmed: 23432691
Cell Mol Life Sci. 2006 May;63(9):1028-37
pubmed: 16465446
Int J Mol Sci. 2022 Dec 30;24(1):
pubmed: 36614086
J Pathol. 2017 Mar;241(4):534-546
pubmed: 27976373
Br J Haematol. 1998 Oct;103(1):110-23
pubmed: 9792297
Mol Cancer Ther. 2013 Aug;12(8):1402-16
pubmed: 23699658
Front Immunol. 2017 Sep 07;8:1097
pubmed: 28936211
Cancer Treat Rev. 2003 May;29 Suppl 1:11-9
pubmed: 12738239
Int J Mol Sci. 2022 May 28;23(11):
pubmed: 35682744
Histopathology. 2015 May;66(6):873-83
pubmed: 25387851
J Clin Invest. 1993 Apr;91(4):1541-52
pubmed: 8386190
Br J Haematol. 2007 Aug;138(4):446-58
pubmed: 17593251
J Cancer. 2019 Jun 2;10(14):3239-3245
pubmed: 31289595
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
J Biol Chem. 2001 Feb 9;276(6):3983-90
pubmed: 11053440
Leukemia. 2004 Mar;18(3):394-400
pubmed: 14671631
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Curr Pharm Des. 2017;23(32):4745-4757
pubmed: 28699539
J Clin Invest. 1994 Apr;93(4):1380-7
pubmed: 8163642
Haematologica. 2002 Aug;87(8):836-45
pubmed: 12161360
Int J Mol Sci. 2021 Oct 08;22(19):
pubmed: 34639203
Clin Exp Metastasis. 2014 Jun;31(5):585-93
pubmed: 24807734
J Leukoc Biol. 2009 Jun;85(6):905-10
pubmed: 19276179
J Cell Biochem. 2005 Jul 1;95(4):827-39
pubmed: 15838884
Blood Adv. 2021 Sep 28;5(18):3656-3667
pubmed: 34470047
Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9
pubmed: 17913510
Cancer Metastasis Rev. 2007 Jun;26(2):319-31
pubmed: 17458507
Int J Oncol. 2017 Jul;51(1):104-114
pubmed: 28498427
Am J Physiol. 1990 Oct;259(4 Pt 1):L262-9
pubmed: 2221087
Blood Rev. 2013 Nov;27(6):261-7
pubmed: 24054128
Mol Cancer Res. 2011 Oct;9(10):1319-28
pubmed: 21824975
J Clin Invest. 1991 Mar;87(3):1091-7
pubmed: 1847936
Clin Exp Immunol. 1990 May;80(2):252-6
pubmed: 2357854
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Blood. 2016 Nov 3;128(18):2241-2252
pubmed: 27625360
Cancer Immunol Res. 2022 Dec 2;10(12):1506-1524
pubmed: 36206576
Chin Med Sci J. 2016 Sep 20;31(3):155-160
pubmed: 27733222
J Biol Chem. 2002 Dec 6;277(49):46932-9
pubmed: 12297505
Am J Pathol. 2014 Dec;184(12):3384-93
pubmed: 25310970
Oncogene. 2006 Jul 20;25(31):4257-66
pubmed: 16518413
Front Immunol. 2018 Apr 04;9:574
pubmed: 29670612
Front Oncol. 2022 Jul 07;12:933666
pubmed: 35875135
Ann Med. 2010 Apr;42(3):161-70
pubmed: 20384432
Oncol Lett. 2015 Oct;10(4):2403-2409
pubmed: 26622860
Br J Haematol. 2000 Jun;109(4):815-22
pubmed: 10929035
Curr Pharm Des. 2011;17(19):1970-8
pubmed: 21711234
Pharmaceutics. 2021 Mar 17;13(3):
pubmed: 33802877
Nat Med. 2011 Mar;17(3):320-9
pubmed: 21383745
Gut. 2015 Apr;64(4):589-600
pubmed: 24848264
Immunity. 2016 Feb 16;44(2):246-58
pubmed: 26872695
Cells. 2020 Nov 24;9(12):
pubmed: 33255171
Mol Cancer. 2019 Dec 5;18(1):177
pubmed: 31805946
Br J Haematol. 2020 Jan;188(2):283-294
pubmed: 31423579
Ann Hematol. 2013 May;92(5):669-77
pubmed: 23334187
Crit Rev Oncol Hematol. 2011 Nov;80(2):225-40
pubmed: 21236697
Leukemia. 2013 Mar;27(3):702-10
pubmed: 22996336
Int J Mol Sci. 2022 Mar 14;23(6):
pubmed: 35328533
Front Bioeng Biotechnol. 2023 Jan 10;10:1075715
pubmed: 36704300
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35428704
Adv Drug Deliv Rev. 2017 May 15;114:206-221
pubmed: 28449873
Nat Commun. 2019 May 22;10(1):2272
pubmed: 31118418
Br J Haematol. 2012 Aug;158(3):336-46
pubmed: 22583117
Int J Mol Sci. 2021 Apr 16;22(8):
pubmed: 33923400
J Leukoc Biol. 2017 Aug;102(2):265-275
pubmed: 28254840
J Cell Biol. 2001 Feb 19;152(4):741-52
pubmed: 11266465
Heliyon. 2022 Dec 01;8(12):e11998
pubmed: 36478848
PLoS Med. 2020 Nov 4;17(11):e1003323
pubmed: 33147277
Oncotarget. 2016 Sep 13;7(37):60698-60711
pubmed: 27474171
Am J Hematol. 2009 Jul;84(7):401-7
pubmed: 19507209
J Oncol. 2013;2013:183602
pubmed: 23431298
Semin Cell Dev Biol. 2010 Feb;21(1):33-9
pubmed: 19896548
Oncogene. 2008 Jan 24;27(5):663-74
pubmed: 17667938
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64
pubmed: 11818541
Oncotarget. 2014 Nov 30;5(22):11283-96
pubmed: 25526031